MIL95 / Beijing Mabworks Biotech, Keymed Biosciences - LARVOL DELTA

A Clinical Study of MIL95 in Advanced Malignancies. (clinicaltrials.gov) - P1 | N=58 | Recruiting | Sponsor: Beijing Mabworks Biotech Co., Ltd. | Trial completion date: Nov 2023 ➔ Nov 2024 | Trial primary completion date: May 2023 ➔ Dec 2022

Metastases • Trial completion date • Trial primary completion date • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor

A first-in-human study of MIL95, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors and lymphomas. (ASCO 2023) - P1 | "MIL95 was well tolerated at 1 mg/kg priming dose following by maintenance doses of up to 45 mg/kg weekly. Further antitumor activity may need to be combined with other therapies. Clinical trial information: NCT04651348."

Clinical • Metastases • P1 data • Anemia • Biliary Cancer • Cholangiocarcinoma • Fatigue • Gastrointestinal Cancer • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Leukopenia • Lymphoma • Oncology • Solid Tumor

A Clinical Study of MIL95 in Advanced Malignancies. (clinicaltrials.gov) - P1 | N=58 | Recruiting | Sponsor: Beijing Mabworks Biotech Co., Ltd. | Trial completion date: Nov 2022 ➔ Nov 2023 | Trial primary completion date: May 2022 ➔ May 2023

Trial completion date • Trial primary completion date • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor

A Clinical Study of MIL95 in Advanced Malignancies. (clinicaltrials.gov) - P1 | N=58 | Recruiting | Sponsor: Beijing Mabworks Biotech Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor

A Clinical Study of MIL95 in Advanced Malignancies. (clinicaltrials.gov) - P1; N=58; Not yet recruiting; Sponsor: Beijing Mabworks Biotech Co., Ltd.

Clinical • New P1 trial • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor